BTK inhibitors approved in Canada for CLL: Strategies for adverse event management
<p class="p1">Bruton tyrosine kinase (BTK) inhibitors are an effective therapy for the treatment of chronic lymphocytic leukemia (CLL), particularly in patients who present with high-risk features. The first-in-class BTK inhibitor, ibrutinib, is generally tolerable. However, unique a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pappin Communications
2021-07-01
|
| Series: | Canadian Oncology Nursing Journal |
| Online Access: | https://canadianoncologynursingjournal.com/index.php/conj/article/view/1203 |